Cytochrome P450 (P450) 3A4 is the most abundant human P450 and oxidizes a diversity of
substrates, including various drugs, steroids, carcinogens, and macrolide natural products. …

Purpose: To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of
the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-…

The pharmacokinetics of UCN-01 after administration as a 72- or 3-h infusion to cancer
patients in initial Phase I trials displayed distinctive features that could not have been predicted …

Over the last century, human activity has caused significant changes to the activity patterns
of many wildlife species. The wild boar is one species known to change its activity pattern …

Remarkable advances in biotechnology have led to the successful development of many
physiologically active peptides and proteins, including growth factors and cytokmes, as …

UCN‐01 is a protein kinase inhibitor under development as a novel anticancer drug. The
initial pharmacologic features in patients were not predicted from preclinical experiments. The …

The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory
framework for biosimilar has also been established in the US, Japan, and other countries. …

The metabolism of vinorelbine, a new anticancer agent belonging to the vinca alkaloid family,
was investigated in human liver microsomes. Vinorelbine biotransformation consisted of …

The large species difference in the pharmacokinetics/pharmacodynamics of 7-hydroxystaurosporine
(UCN-01) can be partially explained by the high affinity binding of UCN-01 to …

The design and synthesis of a novel piperidine series of farnesyltransferase (FTase)
inhibitors with reduced potential for metabolic glucuronidation are described. The various …